| Symbol | GH |
|---|---|
| Name | GUARDANT HEALTH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 505 PENOBSCOT DRIVE, REDWOOD CITY, California, 94063, United States |
| Telephone | +1 855 698-8887 |
| Fax | — |
| — | |
| Website | https://www.guardanthealth.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001576280 |
| Description | Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The companys pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Additional info from NASDAQ: |
📋 Talasaz AmirAli (Officer) plans to sell 260K shares of Guardant Health, Inc. (at $100.32 each, total $26.1M) Filed: May 12, 2026 | ID: 000154
Read more(30% Negative) GUARDANT HEALTH, INC. (GH) Reports Q2 2026 Financial Results
Read moreGuardant Health, Inc. - Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Read moreGuardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Read moreGuardant Health, Inc. - Guardant Health Receives FDA Approval forGuardant360® CDx as a Companion Diagnostic for Arvinas andPfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Read moreGuardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Read moreDirector Krognes Steve E. 🟡 adjusted position in 0 shares (1 derivative) of Guardant Health, Inc. (GH) Transaction Date: Apr 30, 2026 | Filing ID: 000011
Read moreGuardant Health, Inc. - Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
Read moreGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
Read moreNew Form SCHEDULE 13G - Guardant Health, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000589 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07436637 | Guardant Shield Colorectal Cancer Screening | Na | Colorectal Cancer | Not_Yet_Recruiting | 2026-05-30 | 2027-04-01 | ClinicalTrials.gov |
| NCT07004413 | Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RA… | Phase3 | Colorectal Cancer Metastatic | Not_Yet_Recruiting | 2026-01-01 | 2031-01-01 | ClinicalTrials.gov |
| NCT06880055 | Shield Post-Approval Study Protocol | — | Colo-rectal Cancer | Recruiting | 2025-07-14 | 2030-12-01 | ClinicalTrials.gov |
| NCT06444542 | Understanding Patient Preference on Colorectal Cancer Screening Options-PSU | — | Colo-rectal Cancer | Completed | 2024-09-16 | 2025-12-18 | ClinicalTrials.gov |
| NCT05935384 | SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation | — | Non-small Cell Lung Cancer | Recruiting | 2023-10-25 | 2030-12-30 | ClinicalTrials.gov |
| NCT06119425 | Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Prac… | Na | Cancer Colon | Completed | 2023-10-12 | 2025-04-30 | ClinicalTrials.gov |
| NCT05703243 | Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liqu… | — | Stage III Solid Tumors | Unknown | 2023-02-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT05716477 | Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved… | — | Colorectal Carcinoma | Completed | 2022-12-23 | 2024-11-30 | ClinicalTrials.gov |
| NCT05117840 | Screening for High Frequency Malignant Disease | — | Lung Cancer | Active_Not_Recruiting | 2022-01-13 | 2026-12-31 | ClinicalTrials.gov |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Bladder Carcinoma | Recruiting | 2021-09-07 | 2029-08-01 | ClinicalTrials.gov |
| NCT05641870 | Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanc… | — | Lung Cancer | Unknown | 2021-02-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT04497285 | Real World Study Using Comprehensive Genomic Data on the Next Treatment Decisio… | — | Metastatic Breast Cancer | Active_Not_Recruiting | 2020-10-20 | 2026-11-30 | ClinicalTrials.gov |
| NCT04436393 | Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Br… | — | Advanced Breast Cancer | Completed | 2020-07-02 | 2022-03-17 | ClinicalTrials.gov |
| NCT04410796 | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase2 | Metastatic Non-small Cell Lung Cancer | Recruiting | 2020-05-28 | 2026-05-01 | ClinicalTrials.gov |
| NCT04136002 | Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode | — | Colorectal Cancer | Completed | 2019-10-08 | 2025-08-05 | ClinicalTrials.gov |
| NCT04087473 | Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC | — | Non-small Cell Lung Cancer | Recruiting | 2019-08-23 | 2025-12-31 | ClinicalTrials.gov |
| NCT03625557 | Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Recor… | — | Non-Hematologic Malignancy | Completed | 2019-04-30 | 2020-04-16 | ClinicalTrials.gov |
| NCT03477474 | Registry of Guardant360® Use and Outcomes In People With Advanced Cancer | — | Non-small Cell Lung Cancer Metastatic | Terminated | 2018-04-06 | 2019-09-01 | ClinicalTrials.gov |
| NCT03774758 | Biomarkers for Risk Stratification in Lung Cancer | — | Nodule Solitary Pulmonary | Recruiting | 2017-12-17 | 2025-12-31 | ClinicalTrials.gov |
| NCT03791034 | Cell Free DNA for the Diagnosis and Treatment in Early NSCLC | — | Non-small Cell Lung Cancer | Recruiting | 2017-08-28 | 2026-12-31 | ClinicalTrials.gov |
| NCT02967770 | Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Meta… | Phase2 | Metastatic Pancreatic Cancer | Withdrawn | 2016-11-01 | 2018-08-30 | ClinicalTrials.gov |
| NCT03248089 | Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP) | — | Lung Cancer | Completed | 2016-07-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT03746262 | Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-S… | — | Non Small Cell Lung Cancer | Completed | 2016-05-13 | 2018-08-10 | ClinicalTrials.gov |
| NCT03615443 | Noninvasive vs. Invasive Lung Evaluation | — | Non-Small Cell Lung Cancer | Completed | 2016-02-12 | 2020-11-23 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard of Care Second Line Therapy | Drug | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |
| Molecularly Tailored Second Line Therapy | Drug | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |
| Guardant360 | Other | Preclinical | Lung Cancer | COMPLETED | NCT03248089 |
| Guardant360 | Other | Preclinical | Non-Small Cell Lung Cancer | COMPLETED | NCT03615443 |
| Guardant360 test | Other | Preclinical | Advanced Breast Cancer | COMPLETED | NCT04436393 |
| Genomic and methylation analysis in liquid biopsy | Other | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Chemoradiation treatment regimen and maintenance (if amenable) | Drug | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Characterization of the tumoral tissue genomic alterations | Other | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Sample collection | Other | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| EORTC QLQ-30 | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05703243 |
| Comprehensive liquid molecular panel test | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05703243 |
| Survey Administration | Other | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| Biospecimen Collection | Other | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| Guardant Health ct-DNA LUNAR assay | Other | Preclinical | Nodule Solitary Pulmonary | RECRUITING | NCT03774758 |
| Guardant360 ctDNA assay | Other | Phase PHASE3 | Colorectal Cancer Metastatic | NOT_YET_RECRUITING | NCT07004413 |
| FOLFIRI+cetuximab | Other | Phase PHASE3 | Colorectal Cancer Metastatic | NOT_YET_RECRUITING | NCT07004413 |
| blood sample collection and collection of tumor tissue block | Other | Preclinical | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04497285 |
| Guardant360 | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05935384 |
| Guardant Reveal | Other | Preclinical | Bladder Carcinoma | RECRUITING | NCT05059444 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Osimertinib | Other | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| blood-based CRC screening | Other | Approved | Cancer Colon | COMPLETED | NCT06119425 |
| Guardant Shield | Other | Preclinical | Colo-rectal Cancer | COMPLETED | NCT06444542 |
| Shield Blood Test for colo-rectal cancer Screening | Other | Preclinical | Colo-rectal Cancer | RECRUITING | NCT06880055 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Blood Sample Collection | PROCEDURE | Approved | Colorectal Cancer | NOT_YET_RECRUITING | NCT07436637 |
| Screening Reminder | BEHAVIORAL | Approved | Colorectal Cancer | NOT_YET_RECRUITING | NCT07436637 |
| FOLFIRI+cetuximab | DRUG | Phase PHASE3 | Colorectal Cancer Metastatic | NOT_YET_RECRUITING | NCT07004413 |
| Guardant Shield | BEHAVIORAL | Preclinical | Colo-rectal Cancer | COMPLETED | NCT06444542 |
| Survey Administration | OTHER | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| Biospecimen Collection | PROCEDURE | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| EORTC QLQ-30 | OTHER | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05703243 |
| Chemoradiation treatment regimen and maintenance (if amenable) | DRUG | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Sample collection | PROCEDURE | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Low-dose CT scan | DEVICE | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| blood sample collection and collection of tumor tissue block | OTHER | Preclinical | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04497285 |
| Pemetrexed | DRUG | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Carboplatin | DRUG | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Osimertinib | DRUG | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Standard of Care Second Line Therapy | DRUG | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |
| Molecularly Tailored Second Line Therapy | OTHER | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |